Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINC1 | P01008 | 2/20 | 0.40 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.33 |
| ▸ | CCL2 | P13500 | 1/20 | 0.33 |
| ▸ | CCL5 | P13501 | 1/20 | 0.33 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.33 |
| ▸ | FGF1 | P05230 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 4/20 | 0.30 |
| ▸ | FGF2 | P09038 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14227801 | 0.87 | SERPINC1 (0.37) | SERPINC1FGF1F10FGF2 | |
| SCHEMBL12458594 | 0.83 | SERPINC1 (0.59) | SERPINC1CXCL10CXCL8CCL2CCL5 | |
| SCHEMBL17521735 | 0.83 | SERPINC1 (0.40) | SERPINC1CXCL10CXCL8CCL2CCL5 | |
| SCHEMBL17902153 | 0.81 | SERPINC1 (0.39) | SERPINC1CXCL10CXCL8CCL2CCL5 | |
| SCHEMBL13873870 | 0.78 | SERPINC1 (0.57) | SERPINC1CXCL10CXCL8CCL2CCL5 | |
| SCHEMBL12799309 | 0.75 | SERPINC1 (0.68) | SERPINC1CXCL10CXCL8CCL2CCL5 | |
| SCHEMBL14959633 | 0.73 | SERPINC1 (0.57) | SERPINC1CXCL10CXCL8CCL2CCL5 | |
| SCHEMBL15896273 | 0.70 | SERPINC1 (0.69) | SERPINC1CXCL10CXCL8CCL2CCL5 | |
| SCHEMBL17521737 | 0.69 | SERPINC1 (0.35) | SERPINC1F10 | |
| SCHEMBL17521736 | 0.67 | MDK (0.42) | FGF1F2FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9259389-B2 | Pharmaceutical oral dosage form containing a synthetic oligosaccharide | ENDOTIS PHARMA (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20120316132-A1 | PHARMACEUTICAL ORAL DOSAGE FORM CONTAINING A SYNTHETIC OLIGOSACCHARIDE | CATALENT FRANCE BEINHEIM SA | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316132-A1 | PHARMACEUTICAL ORAL DOSAGE FORM CONTAINING A SYNTHETIC OLIGOSACCHARIDE | LIPA, SORD, SI | SERPINC1 919/4885CXCL10 3119/4885CXCL8 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.